This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Hoeven, J. J.M. Articles by Lammertsma, A. A. Search for Related Content PubMed PubMed Citation Articles by van der Hoeven, J. J.M. Articles by Lammertsma, A. A. Social Bookmarking                            What's this?

¹⁸F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer

Jacobus J.M. van der Hoeven, Nanda C. Krak, Otto S. Hoekstra, Emile F.I. Comans, Robert P.A. Boom, Dick van Geldere, Sybren Meijer, Elsken van der Wall, Jan Buter, Herbert M. Pinedo, Gerrit J.J. Teule, Adriaan A. Lammertsma

From the Departments of Nuclear Medicine and PET Research, Clinical Epidemiology and Biostatics, Surgery, and Medical Oncology, Vrije Universiteit Medical Center, Amsterdam; and Departments of Surgery and Internal Medicine, Ziekenhuis Amstelveen, Amstelveen, the Netherlands.

Address reprint requests to J.J.M. van der Hoeven, MD, Vrije Universiteit University Medical Center, PET Center/Department of Nuclear Medicine, PO Box 7057, 1007 MB Amsterdam, the Netherlands; e-mail: jjho{at}zha.nl

PURPOSE: To prospectively evaluate the effect of adding whole-body ¹⁸F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to conventional screening for distant metastases in patients with locally advanced breast cancer (LABC).

PATIENTS AND METHODS: All women with LABC referred for participation in the LABC Spinoza trial were considered eligible for this study. Patients were included if chest x-ray, bone scan, liver ultrasound, or computed tomography scan performed by the referring physician failed to reveal distant metastases. They underwent whole-body FDG PET scanning before therapy. Patients with subsequently proven distant metastases were switched to alternative forms of chemotherapy, hormonal therapy, or both.

RESULTS: Among the 48 patients evaluated with PET, 14 had abnormal FDG uptake, and metastases were suspected in 12. After simple clinical evaluation (plain x-ray, history), 10 sites that were suggestive of abnormality remained. Further work-up revealed that four sites were metastases. Proven false positivity occurred in one patient with sarcoidosis. In the other five patients, the reason for abnormal FDG uptake (liver, lung, bone) remained unclear, and patients were treated as planned. Eleven months later, distant metastases were found in one patient at sites unrelated to the previous FDG uptake.

CONCLUSION: The addition of FDG PET to the standard work-up of patients with LABC may lead to the detection of unexpected distant metastases. This may contribute to a more realistic stratification between patients with true stage III breast cancer and those who are in fact suffering from stage IV disease. Abnormal PET findings should be confirmed to prevent patients from being denied appropriate treatment.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Deceased.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1--Overview, Detection, and Staging J. Nucl. Med., April 1, 2009; 50(4): 569 - 581. [Abstract] [Full Text] [PDF]

				S. Carkaci, H. A. Macapinlac, M. Cristofanilli, O. Mawlawi, E. Rohren, A. M. Gonzalez Angulo, S. Dawood, E. Resetkova, H. T. Le-Petross, and W.-T. Yang Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data J. Nucl. Med., February 1, 2009; 50(2): 231 - 238. [Abstract] [Full Text] [PDF]

				D. Fuster, J. Duch, P. Paredes, M. Velasco, M. Munoz, G. Santamaria, M. Fontanillas, and F. Pons Preoperative Staging of Large Primary Breast Cancer With [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Compared With Conventional Imaging Procedures J. Clin. Oncol., October 10, 2008; 26(29): 4746 - 4751. [Abstract] [Full Text] [PDF]

				J. Emmering, N. C. Krak, J. J. M. Van der Hoeven, M. D. Spreeuwenberg, J. W. R. Twisk, S. Meijer, H. M. Pinedo, and O. S. Hoekstra Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology Ann. Onc., September 1, 2008; 19(9): 1573 - 1577. [Abstract] [Full Text] [PDF]

				S. Mahner, S. Schirrmacher, W. Brenner, L. Jenicke, C. R. Habermann, N. Avril, and J. Dose-Schwarz Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer Ann. Onc., July 1, 2008; 19(7): 1249 - 1254. [Abstract] [Full Text] [PDF]

				N. C. Hodgson and K. Y. Gulenchyn Is There a Role for Positron Emission Tomography in Breast Cancer Staging? J. Clin. Oncol., February 10, 2008; 26(5): 712 - 720. [Abstract] [Full Text] [PDF]

				S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff Locally Advanced and Inflammatory Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790. [Full Text] [PDF]

				D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]

				B Klaeser, O Wiederkehr, D Koeberle, A Mueller, B Bubeck, and B Thuerlimann Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer Ann. Onc., August 1, 2007; 18(8): 1329 - 1334. [Abstract] [Full Text] [PDF]

				A Cardillo, C De Cicco, G Paganelli, R Ghisini, G Peruzzotti, A Balduzzi, A Goldhirsch, N Rotmensz, P Veronesi, A Luini, et al. Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery Ann. Onc., February 1, 2007; 18(2): 394 - 395. [Full Text] [PDF]

				A. Chung, D. Liou, S. Karlan, A. Waxman, K. Fujimoto, M. Hagiike, and E. H. Phillips Preoperative FDG-PET for Axillary Metastases in Patients With Breast Cancer Arch Surg, August 1, 2006; 141(8): 783 - 789. [Abstract] [Full Text] [PDF]

				E. R. Port, H. Yeung, M. Gonen, L. Liberman, J. Caravelli, P. Borgen, and S. Larson 18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma Ann. Surg. Oncol., May 1, 2006; 13(5): 677 - 684. [Abstract] [Full Text] [PDF]

				E. R. Port and H. S. Cody III Editorial: Don't Give up your Gamma Probe Ann. Surg. Oncol., September 1, 2004; 11(9): 813 - 814. [Full Text] [PDF]